VolitionRx Limited (NYSEAMERICAN:VNRX) Sees Large Decline in Short Interest

VolitionRx Limited (NYSEAMERICAN:VNRX) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 570,500 shares, a decrease of 20.3% from the December 15th total of 715,700 shares. Based on an average daily volume of 262,100 shares, the short-interest ratio is currently 2.2 days.

VolitionRx Price Performance

Shares of VNRX stock traded down $0.00 on Friday, hitting $0.64. 748 shares of the stock traded hands, compared to its average volume of 83,730. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The company has a market capitalization of $40.44 million, a price-to-earnings ratio of -1.14 and a beta of 1.59.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.